Longboard Pharmaceuticals, Inc. ((LBPH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Longboard Pharmaceuticals, Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Dravet Syndrome.’ The study aims to evaluate the effectiveness and safety of LP352 in managing seizures associated with Dravet Syndrome, a severe form of epilepsy, highlighting its potential significance in improving patient outcomes.
The intervention being tested is LP352, an experimental drug administered orally or via G-tube/PEG tube, designed to reduce seizure frequency in Dravet Syndrome patients. The study also includes a placebo group for comparison.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, aiming to establish LP352’s efficacy and safety.
The study began on October 2, 2024, and is currently recruiting participants. The primary completion and estimated study completion dates have not been specified, but the last update was submitted on July 8, 2025, indicating ongoing progress.
The outcome of this study could significantly impact Longboard Pharmaceuticals’ stock performance and investor sentiment, especially if LP352 proves effective. Success could position Longboard favorably within the competitive landscape of epilepsy treatments, potentially influencing market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.